Parkinson disease

Nature Reviews Disease Primers, Journal Year: 2017, Volume and Issue: 3(1)

Published: March 22, 2017

Language: Английский

---

Glucagon-like peptide 1 (GLP-1)

Molecular Metabolism, Journal Year: 2019, Volume and Issue: 30, P. 72 - 130

Published: Sept. 30, 2019

Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential.Among the numerous metabolic effects of GLP-1 are glucose-dependent stimulation insulin secretion, decrease gastric emptying, inhibition food intake, increase natriuresis and diuresis, modulation rodent b-cell proliferation.GLP-1 also has cardio-and neuroprotective effects, decreases inflammation apoptosis, implications for learning memory, reward behavior, palatability.Biochemically modified enhanced potency sustained action, receptor agonists successfully in clinical use treatment type-2 diabetes, several GLP-1-based pharmacotherapies evaluation obesity.Scope review: In this review, we provide detailed overview on nature its pharmacology discuss therapeutic various diseases.Major conclusions: Since discovery, emerged as pleiotropic myriad functions that go well beyond classical identification an incretin hormone.The beneficial render interesting candidate development to treat obesity, neurodegenerative disorders

Language: Английский

---

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The Lancet, Journal Year: 2017, Volume and Issue: 390(10103), P. 1664 - 1675

Published: Aug. 3, 2017

Language: Английский

---

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Sept. 22, 2023

Abstract Microglia activation is observed in various neurodegenerative diseases. Recent advances single-cell technologies have revealed that these reactive microglia were with high spatial and temporal heterogeneity. Some identified specific states correlate pathological hallmarks are associated functions. both exert protective function by phagocytosing clearing protein aggregates play detrimental roles due to excessive uptake of aggregates, which would lead microglial phagocytic ability impairment, neuroinflammation, eventually neurodegeneration. In addition, peripheral immune cells infiltration shapes into a pro-inflammatory phenotype accelerates disease progression. also act as mobile vehicle propagate aggregates. Extracellular vesicles released from autophagy impairment all contribute progression Thus, enhancing phagocytosis, reducing microglial-mediated inhibiting exosome synthesis secretion, promoting conversion considered be promising strategies for the therapy Here we comprehensively review biology diseases, including Alzheimer’s disease, Parkinson’s multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, dementia Lewy bodies Huntington’s disease. We summarize possible microglia-targeted interventions treatments against diseases preclinical clinical evidence cell experiments, animal studies, trials.

Language: Английский

---

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2014, Volume and Issue: 1842(9), P. 1693 - 1706

Published: June 17, 2014

Language: Английский

---

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Drug Discovery Today, Journal Year: 2016, Volume and Issue: 21(5), P. 802 - 818

Published: Feb. 3, 2016

Growing evidence suggests that agonists of the glucagon-like peptide 1 (GLP-1) receptor provide neuroprotection across a range experimental models Parkinson's disease (PD) and, recently, small proof-of-concept, open-label human trial exenatide in treatment moderate severity PD appeared to show persistent improvements motor and cognitive function. The underlying mechanisms action remain unclear, but as for potential use GLP-1 treating several neurodegenerative mounts, with clinical trials analogues Alzheimer's (AD) currently underway, here we review molecular neuroprotective effects laboratory their therapeutic utility particular relevance dementia (PDD).

Language: Английский

---

Insulin resistance and Parkinson’s disease: A new target for disease modification?

Progress in Neurobiology, Journal Year: 2016, Volume and Issue: 145-146, P. 98 - 120

Published: Oct. 1, 2016

Language: Английский

---

Minimal clinically important difference on the Motor Examination part of MDS-UPDRS

Parkinsonism & Related Disorders, Journal Year: 2015, Volume and Issue: 21(12), P. 1421 - 1426

Published: Oct. 25, 2015

Language: Английский

---

Progress towards therapies for disease modification in Parkinson's disease

The Lancet Neurology, Journal Year: 2021, Volume and Issue: 20(7), P. 559 - 572

Published: June 16, 2021

Language: Английский

---

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

Nature Reviews Drug Discovery, Journal Year: 2018, Volume and Issue: 17(11), P. 804 - 822

Published: Sept. 28, 2018

Language: Английский

---